A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.

Trial Details

NCT ID
NCT07647328
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Camizestrant
  • Ribociclib
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Palo Alto, California, United States|37.44188,-122.14302
  • Marietta, Georgia, United States|33.9526,-84.54993
  • Evanston, Illinois, United States|42.04114,-87.69006
  • Edgewood, Kentucky, United States|39.01867,-84.58189

Key Eligibility Criteria

  • Capable of giving signed informed consent.
  • Female or male, must be ≥ 18 years or as per locally allowed age limit for screening.
  • Type of Participant and Disease Characteristics
  • Histologically or cytologically documented diagnosis of ER+, HER2- BC based on local laboratory results and who are not amenable to resection or ra…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →